A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

Stephen Couban; Giulia Benevolo; William Donnellan; Jennifer Cultrera; Steffen Koschmieder; Srdan Verstovsek; Gregory Hooper; Christian Hertig; Maneesh Tandon; Natalie Dimier; Vikram Malhi; Francesco Passamonti

doi:10.1186/s13045-018-0661-x

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

Stephen Couban, Giulia Benevolo, William Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, Gregory Hooper, Christian Hertig, Maneesh Tandon, Natalie Dimier, Vikram Malhi, Francesco Passamonti

科研成果: 期刊稿件 › 文章 › 同行评审

22 引用（Scopus）

源语言	英语
文章编号	122
期刊	Journal of Hematology and Oncology
卷	11
期	1
DOI	https://doi.org/10.1186/s13045-018-0661-x
出版状态	已出版 - 9月 24 2018
已对外发布	是

!!!ASJC Scopus Subject Areas

分子生物学
血液学
肿瘤学
癌症研究

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1186/s13045-018-0661-x

其它文件与链接

引用此

Couban, S., Benevolo, G., Donnellan, W., Cultrera, J., Koschmieder, S., Verstovsek, S., Hooper, G., Hertig, C., Tandon, M., Dimier, N., Malhi, V., & Passamonti, F. (2018). A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis. Journal of Hematology and Oncology, 11(1), 文章 122. https://doi.org/10.1186/s13045-018-0661-x

Couban, S, Benevolo, G, Donnellan, W, Cultrera, J, Koschmieder, S, Verstovsek, S, Hooper, G, Hertig, C, Tandon, M, Dimier, N, Malhi, V & Passamonti, F 2018, 'A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis', Journal of Hematology and Oncology, 卷 11, 号码 1, 122. https://doi.org/10.1186/s13045-018-0661-x

@article{4f624404674347f7bb69f832afa82dd7,

title = "A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis",

keywords = "Hedgehog pathway inhibitor, Hematologic malignances, Hematopoiesis, Myelofibrosis, Ruxolitinib, Vismodegib",

author = "Stephen Couban and Giulia Benevolo and William Donnellan and Jennifer Cultrera and Steffen Koschmieder and Srdan Verstovsek and Gregory Hooper and Christian Hertig and Maneesh Tandon and Natalie Dimier and Vikram Malhi and Francesco Passamonti",

note = "Publisher Copyright: {\textcopyright} 2018 The Author(s).",

year = "2018",

month = sep,

day = "24",

doi = "10.1186/s13045-018-0661-x",

language = "English",

volume = "11",

journal = "Journal of Hematology and Oncology",

issn = "1756-8722",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

AU - Couban, Stephen

AU - Benevolo, Giulia

AU - Donnellan, William

AU - Cultrera, Jennifer

AU - Koschmieder, Steffen

AU - Verstovsek, Srdan

AU - Hooper, Gregory

AU - Hertig, Christian

AU - Tandon, Maneesh

AU - Dimier, Natalie

AU - Malhi, Vikram

AU - Passamonti, Francesco

PY - 2018/9/24

Y1 - 2018/9/24

KW - Hedgehog pathway inhibitor

KW - Hematologic malignances

KW - Hematopoiesis

KW - Myelofibrosis

KW - Ruxolitinib

KW - Vismodegib

UR - http://www.scopus.com/inward/record.url?scp=85053820642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053820642&partnerID=8YFLogxK

U2 - 10.1186/s13045-018-0661-x

DO - 10.1186/s13045-018-0661-x

M3 - Article

C2 - 30249277

AN - SCOPUS:85053820642

SN - 1756-8722

VL - 11

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

IS - 1

M1 - 122

ER -

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

!!!ASJC Scopus Subject Areas

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此